Opinion
Video
Exploring The Future of NF1-PN Management
Panelists discuss the future of NF1-associated plexiform neurofibromas management, highlighting the potential for advances in targeted therapies, gene therapies, and personalized medicine to offer more effective, tailored treatments, while emphasizing early detection, improved imaging, and a greater focus on quality of life through psychosocial support, pain management, and functional rehabilitation.
Summary for Physicians
Future of NF1-PN Management
The management of neurofibromatosis type 1–associated plexiform neurofibromas (NF1-PN) is likely to evolve significantly over the next few years with advances in targeted therapies, gene therapies, and personalized medicine. As our understanding of the RAS/MAPK pathway and other molecular drivers deepens, we can expect more effective and tailored treatments, such as combination therapies and gene editing techniques. Early detection through biomarkers and improved imaging will allow for earlier intervention, potentially preventing tumor progression and improving long-term outcomes.
Additionally, long-term disease management will increasingly focus on quality of life, with an emphasis on psychosocial support, pain management, and functional rehabilitation. Advances in precision medicine will enable clinicians to better identify the right therapies for each patient, improving efficacy while minimizing adverse effects.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
